RC1012 injection (allo-DNT cells)

BIOLOGICAL2 trials

Sponsors

Guangdong Ruishun Biotech Co., Ltd

Conditions

Acute Myeloid Leukemia

Phase 1

Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML

Guangdong Ruishun Biotech Co., LtdAcute Myeloid Leukemia

Start: 2021-01-14End: 2024-12-31Target: 36Updated: 2023-05-19

RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT

RecruitingNCT05858814

Guangdong Ruishun Biotech Co., LtdAcute Myeloid Leukemia

Start: 2023-05-04End: 2026-06-24Target: 72Updated: 2023-05-19

Related Papers

Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients after allo-HSCT: A phase I trial.

Journal of Clinical Oncology2025-05-281 citations

Increase of Dnts Correlated with Clinic Outcome after Allogeneic DNT Cells Infusion in r/r AML Patients

Blood2023-11-021 citations